NICE backs Bayer's Xarelto in new stroke and heart attack pr...

Bayer’s Xarelto (rivaroxaban) can be funded by the NHS to prevent strokes and heart attacks in high-risk adults with coronary artery disease, NICE has said.

Novartis' heart failure drug misses expanded use trial targe...

Novartis has announced that its heart failure drug Entresto has failed in a trial that the company hoped would extend its use to a new group of patients with preserved ejection fraction.

Yale, Mayo and FDA experts aim to rethink heart failure tria...

A group of scientists from Yale University and the Mayo Clinic are to use an Apple Watch app in a bid to rethink clinical trial design in heart failure.

FDA clears Bayer’s Gadavist as first contrast agent for card...

Huami set to launch ECG watches outside China

Huami is to make its new crop of electrocardiogram smartwatches available to international markets, according to a press report.

Biotech Verve launches on mission to replace statins with CR...

Could CRISPR gene editing one day replace the need for cholesterol-lowering drugs such as statins?